NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.42Cr 5.61Cr 5.19Cr 4.79Cr 9.03Cr 616.93Cr 9.19Cr 62Cr 24Cr 302.09Cr 24Cr 24Cr 1.04TCr	P/E 2024 *	-	P/E 2025	-2.81x
Enterprise Value	6.24Cr 5.45Cr 5.04Cr 4.66Cr 8.77Cr 599.2Cr 8.93Cr 60Cr 24Cr 293.41Cr 23Cr 23Cr 1.01TCr	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	31.94%	Yield 2024 *	-	Yield 2025	-

06:54pm	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment	MT
08/07	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board	CI
01/07	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
15/06	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
27/05	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
27/05	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
30/04	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
30/04	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/04	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
20/04	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
02/04	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
09/03	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
12/01	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI

06:31pm	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio	AQ
08/07	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board	AQ
08/07	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy	AQ
01/07	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ
27/05	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-0.78%	+153.00%	-	-	2.14Cr
LONZA GROUP AG	-0.27%	+1.36%	+3.05%	+7.32%	5.04TCr
REVOLUTION MEDICINES, INC.	-1.02%	-3.51%	+384.31%	+588.15%	3.93TCr
IQVIA HOLDINGS INC.	+0.77%	+2.68%	+32.71%	-5.47%	3.47TCr
BEONE MEDICINES AG	+2.27%	+3.62%	+15.99%	+58.07%	3.41TCr
CELLTRION, INC.	+1.68%	-1.40%	+4.23%	+27.34%	2.66TCr
ASCENDIS PHARMA A/S	-0.35%	-4.47%	-	-	1.65TCr
MEDPACE HOLDINGS, INC.	-0.91%	-0.05%	+70.04%	+114.96%	1.53TCr
EUROFINS SCIENTIFIC SE	+0.43%	+3.34%	+14.96%	+17.98%	1.38TCr
ICON PUBLIC LIMITED COMPANY	+0.54%	+2.47%	+16.47%	-30.80%	1.29TCr
Average	+0.24%	-0.41%	+67.72%	+97.19%	2.71TCr
Weighted average by Cap.	+0.37%	-0.32%	+81.70%	+121.68%

	2024	2025
Net sales	-	-
Net income	-2.66Cr -2.32Cr -2.15Cr -1.98Cr -3.73Cr -255.04Cr -3.8Cr -26Cr -10Cr -124.89Cr -9.97Cr -9.75Cr -430.01Cr	-83L -72.53L -67.05L -61.95L -1.17Cr -80Cr -1.19Cr -8Cr -3.14Cr -39Cr -3.12Cr -3.05Cr -134.42Cr
Net Debt	73.47L 64.21L 59.35L 54.84L 1.03Cr 71Cr 1.05Cr 7.08Cr 2.78Cr 35Cr 2.76Cr 2.7Cr 118.99Cr	-18.46L -16.13L -14.91L -13.78L -25.95L -18Cr -26.42L -1.78Cr -69.78L -8.68Cr -69.34L -67.81L -30Cr

Kadimastem Share Price OTC Markets

Stocks

KMSTF

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Latest news : Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile